MXPA00012041A - Process for the fermentative production of l-amino acids employing coryneform bacteria in which the glya gene activity has been decreased - Google Patents
Process for the fermentative production of l-amino acids employing coryneform bacteria in which the glya gene activity has been decreasedInfo
- Publication number
- MXPA00012041A MXPA00012041A MXPA/A/2000/012041A MXPA00012041A MXPA00012041A MX PA00012041 A MXPA00012041 A MX PA00012041A MX PA00012041 A MXPA00012041 A MX PA00012041A MX PA00012041 A MXPA00012041 A MX PA00012041A
- Authority
- MX
- Mexico
- Prior art keywords
- glya
- gene
- amino acids
- bacteria
- sequences
- Prior art date
Links
- 150000008575 L-amino acids Chemical class 0.000 title claims abstract description 26
- 241000186031 Corynebacteriaceae Species 0.000 title claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title claims description 16
- 230000000694 effects Effects 0.000 title description 12
- 230000003247 decreasing Effects 0.000 title 1
- 101700054993 GLYAT Proteins 0.000 claims abstract description 47
- 101700041392 glyA Proteins 0.000 claims abstract description 47
- 101700085378 glyA1 Proteins 0.000 claims abstract description 47
- 230000002068 genetic Effects 0.000 claims abstract description 14
- 241000588724 Escherichia coli Species 0.000 claims abstract description 13
- 230000001264 neutralization Effects 0.000 claims abstract description 4
- 229920000023 polynucleotide Polymers 0.000 claims abstract 7
- 239000002157 polynucleotide Substances 0.000 claims abstract 7
- 230000000295 complement Effects 0.000 claims abstract 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 26
- 239000004473 Threonine Substances 0.000 claims description 18
- 229960002898 threonine Drugs 0.000 claims description 18
- 241000894006 Bacteria Species 0.000 claims description 13
- 230000000875 corresponding Effects 0.000 claims description 13
- 244000005700 microbiome Species 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000000855 fermentation Methods 0.000 claims description 10
- 230000004151 fermentation Effects 0.000 claims description 10
- 230000014509 gene expression Effects 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 7
- 230000003313 weakening Effects 0.000 claims description 7
- 241000186216 Corynebacterium Species 0.000 claims description 6
- 230000002829 reduced Effects 0.000 claims description 6
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine zwitterion Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims description 3
- DTBNBXWJWCWCIK-UHFFFAOYSA-N Phosphoenolpyruvic acid Natural products OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 claims description 3
- 230000001851 biosynthetic Effects 0.000 claims description 3
- 230000003197 catalytic Effects 0.000 claims description 3
- 238000005755 formation reaction Methods 0.000 claims description 3
- 230000037353 metabolic pathway Effects 0.000 claims description 3
- 238000002703 mutagenesis Methods 0.000 claims description 3
- 231100000350 mutagenesis Toxicity 0.000 claims description 3
- 230000037361 pathway Effects 0.000 claims description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-Benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 2
- 108010042687 EC 1.2.3.3 Proteins 0.000 claims description 2
- 108010053763 EC 6.4.1.1 Proteins 0.000 claims description 2
- 108090000854 Oxidoreductases Proteins 0.000 claims description 2
- 102000004316 Oxidoreductases Human genes 0.000 claims description 2
- 102100007000 PC Human genes 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- 101700048478 p2ox Proteins 0.000 claims description 2
- 101700065321 poxB Proteins 0.000 claims description 2
- 241000595586 Coryne Species 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108010043428 EC 2.1.2.1 Proteins 0.000 abstract description 10
- 102000002667 EC 2.1.2.1 Human genes 0.000 abstract description 2
- 230000001629 suppression Effects 0.000 abstract 2
- 241000186254 coryneform bacterium Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 20
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 15
- 229960000318 kanamycin Drugs 0.000 description 15
- 241000186226 Corynebacterium glutamicum Species 0.000 description 14
- 241000319304 [Brevibacterium] flavum Species 0.000 description 14
- 239000002609 media Substances 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 10
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl β-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 10
- 210000004027 cells Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 108091007521 restriction endonucleases Proteins 0.000 description 8
- 102000019394 Serine hydroxymethyltransferase Human genes 0.000 description 7
- 238000009632 agar plate Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000002255 enzymatic Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 229920000272 Oligonucleotide Polymers 0.000 description 6
- 239000000287 crude extract Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001131 transforming Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 210000000349 Chromosomes Anatomy 0.000 description 4
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002759 chromosomal Effects 0.000 description 4
- 238000007374 clinical diagnostic method Methods 0.000 description 4
- -1 for example Chemical class 0.000 description 4
- 239000001963 growth media Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-N Deoxycytidine triphosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N Deoxyguanosine triphosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-J dATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-J 0.000 description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 230000001718 repressive Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 229960001230 Asparagine Drugs 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229960000310 ISOLEUCINE Drugs 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N Linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 108010019653 Pwo polymerase Proteins 0.000 description 2
- 229960001327 Pyridoxal Phosphate Drugs 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 2
- 229960002180 Tetracycline Drugs 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 238000005020 pharmaceutical industry Methods 0.000 description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 101700006259 tagF Proteins 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- PRKQVKDSMLBJBJ-UHFFFAOYSA-N Ammonium carbonate Chemical compound N.N.OC(O)=O PRKQVKDSMLBJBJ-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- DVARTQFDIMZBAA-UHFFFAOYSA-O Ammonium nitrate Chemical compound [NH4+].[O-][N+]([O-])=O DVARTQFDIMZBAA-UHFFFAOYSA-O 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 240000008371 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 241000186146 Brevibacterium Species 0.000 description 1
- 229940041514 Candida albicans extract Drugs 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 241001517047 Corynebacterium acetoacidophilum Species 0.000 description 1
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 1
- 241000133018 Corynebacterium melassecola Species 0.000 description 1
- 241000337023 Corynebacterium thermoaminogenes Species 0.000 description 1
- 101700011961 DPOM Proteins 0.000 description 1
- SQNZJJAZBFDUTD-UHFFFAOYSA-N Durene Chemical compound CC1=CC(C)=C(C)C=C1C SQNZJJAZBFDUTD-UHFFFAOYSA-N 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 101710029649 MDV043 Proteins 0.000 description 1
- 229940045184 Malt extract Drugs 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101700061424 POLB Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 101700054624 RF1 Proteins 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 229920000978 Start codon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 241000958303 Streptomyces achromogenes Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N Tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 229960004319 Trichloroacetic Acid Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N Trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- 230000001488 breeding Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000024881 catalytic activity Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000037342 citrate cycle Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000008246 gaseous mixture Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002518 isoindoles Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000000050 nutritive Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920001522 polyglycol ester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- NESXXUAWVHXRGX-UHFFFAOYSA-M sodium;1-carboxyethenyl hydrogen phosphate Chemical compound [Na+].OP(O)(=O)OC(=C)C([O-])=O NESXXUAWVHXRGX-UHFFFAOYSA-M 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000005460 tetrahydrofolate Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 150000003588 threonines Chemical class 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Abstract
Production of L-amino acids (A) by fermenting an (A)-producing coryneform bacterium in which the glyA (serine hydroxymethyltransferase) gene (I) has been suppressed;enriching (A) in cells or medium, then recovering it. Independent claims are also included for the following:(1) coryneform bacteria in which (I) has been suppressed;(2) the vector pK18mobglyA'(map reproduced), deposited in Escherichia coli as DSM 13170;and (3) isolated polynucleotide (II) selected from:(a) the lacI-tac-5'-glyA unit (2000 bp sequence (S2), defined in the specification) or the lacI-tac-glyA unit (2866 bp sequence (3), defined in the specification);(b) an equivalent of (a) within the degeneracy of the genetic code;(c) a polynucleotide that hybridizes to the complement of (a) or (b);or (d) a polynucleotide that is a functionally neutral sense mutant of (S2) or (S3).
Description
PROCEDURE FOR THE PREPARATION BY FERMENTATION OF L-.AMINOACIDES USING CORINEFORM BACTERIA SUMMARY OF THE INVENTION The invention relates to a process for the preparation of L-amino acids, in which the following steps are carried out: a) fermentation of the coryneproducer bacteria producing of L-amino acids, in which at least the glyA gene is weakened, in particular by means of the separation of the natural promoter, b) enrichment of the desired product in the medium or in the cells of the bacteria, and c) isolated from the L -aminoacids, and eventually bacteria are used in which additional genes of the biosynthetic pathway of the desired L-amino acids are reinforced, or bacteria are used in which at least the metabolic pathways that reduce the formation of the L- are partially deactivated desired amino acids, and the nucleotide sequences of lacI-tac-5'glyA or the lacI-tac-glyA unit.
PROCEDURE FOR THE PREPARATION BY FERMENTATION OF L-AMINOACIDES USING CORINEFORM BACTERIA
DESCRIPTION OF THE INVENTION The object of the invention is a process for the preparation by fermentation of L-amino acids using coryneform bacteria, in which the glyA gene is weakened. STATE OF THE ART L-amino acids are used in animal feed, in human medicine and in the pharmaceutical industry. It is known that these amino acids are produced by fermentation of strains of coryneform bacteria, especially with Corynebacterium glutamicum. Due to the great importance of this group of products, we continuously work to improve these preparation procedures. Process improvements may consist of technical fermentation measures such as agitation and oxygen feed, or the composition of nutritive media such as sugar concentration during fermentation, or post-processing to the form of a product, by means of, for example, ion exchange chromatography or by intrinsic properties of microorganisms. To improve the performance properties of these microorganisms, methods such as mutagenesis, ref: 124576 selection and selection of mutants are used. In this way strains are obtained which are resistant against antimetabolites such as, for example, the threonine analog o.-amino-β-hydroxylaleric acid (AHV) or auxotropes for the regulatory-important amino acids and which produce L-amino acids, such as, for example, threonine . For several years, methods of DNA recombination technique have been used for the improvement of strains of strains that produce L-amino acids of Corynebacterium glutamicum, in which individual biosynthesis genes are amplified and their effect on the production of the L-amino acids. An article on this is among others that of Konoshita ("Glutamicum Acid Bacteria" in Biology of Industrial Microorganisms, Demain and Solomon (Eds.), Benjamin Cummings, London, UK, 1985, 115-142), Hilliger (BioTec 2, 40-44 (1991)), Jetten and Sunskey (Critical Reviews in Biotechnology 15, 73-.103 (1995)) and Sahm et al., (Annuals of the New York Academy of Science 782, 23-39 (1996)) . Task of the Invention The inventors set themselves the task of obtaining new measures to improve the preparation by fermentation of amino acids with coryneform bacteria. Description of the Invention Amino acids are used in human medicine, in the pharmaceutical industry and especially in animal feed. There is therefore a general interest in a new and improved process for the production of amino acids. When L-amino acids are mentioned below, they involve L-threonine or L-isoleucine. The object of the invention is therefore a process for the preparation by fermentation of L-amino acids using coryneform bacteria which in particular already produce the corresponding L-amino acids and in which the nucleotide sequence (glyA gene) coding for the product is weakened genetic glyA, especially expressed at a low level, the desired product is enriched in the medium or in the cells and the L-amino acid is isolated. The strains used preferably already produce L-amino acids before the weakening of the glyA gene. Preferred embodiments are found in the claims. The concept "weakening" describes in this respect the increase in the intracellular activity of one or several enzymes (protein) in a microorganism, which are encoded by the corresponding DNA (here the glyA gene), for which a promoter is used for example , gene or weak allele that encodes the corresponding enzyme with a lower activity, or inactivates the corresponding gene or enzyme (protein) and eventually combine those measurements.
The microorganisms that are the object of the present invention can produce amino acids from glucose, sucrose, lactose, fructose, maltose, melase, starches, cellulose or glycerin and ethanol. It may be a representative of coryneform bacteria, especially of the genus Corynebacterium. In the genus Corynebacterium, mention should be made in particular of the type Corynebacterium gl utamicum, which is known in the art for its ability to produce L-amino acids. Suitable especially of the genus Corynebacterium Corynebacterium glutamicum type strains, are for example the known wild type strains Corynebacterium glutamicum ATCC13032 Corynebacterium acetoglutamicum ATCC15806 Corynebacterium acetoacidophilum ATCC13870 Corynebacterium melassecola ATCC17965 Corynebacterium thermoaminogenes FERM BP-1539 Brevibacterium flavum ATCC13869 ATCCC14067 Brevibacterium lactofermentum ATCC14020 and Brevibacterium divarica.tum and mutants or strains prepared from them that produce L-amino acids', such as for example the strains producing L-threonine Corynebacterium glutamicum ATCC21649 Brevibacterium flavum BB69
Brevibacterium flavum DSM5399 Brevibacterium lactofermentum FERM-BP 269, Brevibacterium lactofermentum TBB-10 and, for example, the strains producing L-isoleucine Corynebacter? Um glutamicum ATCC 14309 Corynebacterium glutamicum ATCC 14310 Corynebacterium glutamicum ATCC 14311 Corynebacterium glutamicum ATCC 15168 Corynebacterium ammoniagenes ATCC 6871. It was found that coryneform bacteria after weakening of the glyA gene produce L-amino acids in improved form. The glyA gene encodes the enzyme serine hydroxymethyltransferase (EC 2.1.2.1). The nucleotide sequence of the glyA gene was described in Japanese publication JP-A-08107788. He . The glyA gene described in the aforementioned texts can be used according to the invention. Furthermore, alleles of the glyA gene can be used, which is obtained through the degeneration of the genetic code or through sense mutations of neutral function. To obtain a weakening, the expression of the glyA gene or the catalytic properties of the gene product can be reduced or deactivated. Eventually both measures can be combined. The reduction of gene expression can be carried out by means of carrying out suitable culture or by means of genetic modification (mutation) of the signal structures of the gene expression. The signal structures of the gene expression are for example repressor genes, activator genes, operators, promoters, attenuators, ribosome binding sites, the start codon and the terminals. Data on this is found by the technician, for example, in patent application WO 96/15246, by Boyd and Murphy (Journal of
Bacteriology 170: 5949 (1088), by Voskuil and Chambliss
(Nucleic Acids Research 26: 3548 (1998), by Jensen and Hammer (Biotechnology and Bioengineering 58: 191 (1998)), by Patek et al. (Microbiology 142: 1297 (1996) and in well-known texts of genetics and molecular biology, as for example the text of Knippers ("Molecular Genetics", 6th edition, Georg Thieme
Verlag, Stuttgart, Germany, 1995) or Winnacker ("Genes and Clones", VCH Verlagsgesellschaft, Weinheim, Germany, 1990). The mutations that lead to a modification or reduction of the catalytic properties of the enzymatic proteins are known from the state of the art; as examples, the works of Qiu and Goodman (Journal of Biological Chemistry 272: 8611-8617 (1997)), Sugimoto et al. (Bioscience Biotechnology and Biochemistry 61: 1760-1762 (1997)) and Mdckel ("Corynebacterium glutamicum threonine hydratase: preservation of the alostric regulation and structure of the enzyme", Jülich Research Center, Jül-2906 , ISSN09442952, Jülich, Germany, 1994). Abstracts can be found in well-known textbooks on genetics and molecular biology, such as von Hagemann's ("General genetics", Gustav Fischer Verlag, Sttutgart, 1986). Transitions, transversions, insertions and deletions are considered as mutations. Depending on the effect of the amino acid exchange on enzymatic activity, there is talk of missense mutations or nonsense mutations. The insertions or deletions of at least one pair of bases in a gene lead to mutations by shift of the labeling (frame shift mutations) that as a consequence false amino acids are formed or interrupt the translation permanently. Deletions of multiple codons typically lead to a complete reduction of enzyme activity. Instructions to achieve such mutations belong to the state of the art and can be obtained from known texts on genetics and molecular biology, such as the text of Knippers ("Molecular Genetics", 6th edition, Georg Thieme Verlag, Stuttgar, Germany, 1995) or by Winnacker ("Genes and Clones", VCH Verlagsgesellschaft, Weinheim, Germany, 1990) or "Hagemann's (" General Genetics "; Gustav Fischer Verlag, Stuttgart, 1986). For example, the glyA gene was weakened by the removal of the natural promoters and the binding of an upstream regulating control element. The lacl-tac system was used as a control element. To achieve the introduction of the lacl-tac system upstream of the chromosomal gene glyA, the integration plasmid pKldmobglyA 'was prepared (figure 1). Plasmid pKldmonglyA "contains the tac promoter (Amann et al., Gene 25: 167-178 (1983); de Boer et al., Proceedings of the National Academy of Sciences of the United States of America USA 80: 21-25 ( 1983)) and directly downstream of the promoter tac a 5 'terminal sequence of the glyA gene represented in SEQ ID No. 1. The plasmid also contains the lacl gene encoding the Lac inhibitor (Farabaugh, Nature 274;: 765-769 (1978) Stark et al., Gene 51: 255-267 (1987).) The sequence of the lacI-tac-5'glyA unit is represented in SEQ ID No. 2. Plasmid pKldmobglyA 'can be replicated in Escherichia coli but not in Corynebacterium glutamicum After the transformation and homologous recombination by means of a process of "cross-over" of integration effect an intact copy of the glyA gene is obtained, whose expression can be controlled or regulated by means of the element of lacl-tac control placed upstream and an inactive copy truncated at the 3 'terminal of the gly gene A of the natural promoter. The sequence of the lacI-tac-glyA unit is represented in SEQ. ID. No. 3. SEQ. ID. No. 4 shows the known amino acid sequence of the genetic product glyA. By addition of suitable concentrations of the lactose analogue isopropylthiogalactoside (Fürste et al., Gene 48, 119-131 (1986)) the expression of the glyA gene can be controlled or the cellular content of serine hydroxymethyltransferase can be weakened or adjusted. Other indications and clarifications about integration mutagenesis are given by Schwarzer and
Pühler (Bio / Technology 9, 84-87 (991)), Peters-Wendisch et al., (Microbiology 144, 915-927 (1998)) or Fitzpatrick et al.
(Applied Microbiology Biotechnology 42, 575-580 (1994)). An example of an amino acid-producing strain of coryneform bacteria with the weakened glyaA gene is that of Corynebacterium gl utamicum DM368-2:: pK18mobglyA 'producing threonine. Additionally, it may be advantageous for the production of amino acids, in addition to the weakening of the glyA gene, to reinforce one or more enzymes of the biosynthetic pathway, of glycolysis, the anapleoric, the citric acid cycle or the export of amino acids.
Thus for example for the preparation of L-threonine, the homing gene can be simultaneously over-expressed to homoserine dihydrogenase (Peoples et al., Molecular Microbiology 2, 63-72 (1988)) or the homofer allele encoding the dihydrogenase to "feedback-resistant" homoserin (Archer et al., Gene 107, 53-59 (1991)) and / or • the gap gene encoding glyceraldehyde 3-phosphate dihydrogenase (Eikmanns (1992). Bacteriology 174: 6076-6086), or • the pyc gene encoding pyruvate carboxylase (Peters-Wendisch et al., Microbiology 144: 915-927 (1998)), or • the mqo gene encoding malate oxidoreductase: quinone (Molenaar et al., European Journal of
Biochemistry 254, 395-403 (1998)), or • the thrE gene coding for the export of threonine (DE 199 41 478.5, DSM 12840). It can also be advantageous for the production of amino acids, in addition to the glyA gene, simultaneously weaken
• the pck gene encoding phosphoenolpyruvate carboquinase (DE 199 50 409.1; DSM 13047) and / or • the poxB gene coding for pyruvate oxidase (DE 199 51 975.7; DSM 13114) can also be advantageous for the production of amino acids corresponding to the weakening of the glyA gene, avoid unwanted side reactions
(Nakayama: "Breeding of .Amino Acid Producing Micro-organisms", in: Overpoduction of Microbial Products,
Kru phanzl, Sikytam Vanek (eds.); Academic Press, London,
UK, 1982). The culture medium used must suitably be sufficient for the requirements of the microorganisms in question. The description of culture media of different microorganisms can be found in the manual "Manual of Methods for General Bacteriology" of the American Society of Bacteriology (Washington D.C., US, 1981). As a carbon source, sugars and carbohydrates can be used, such as glucose, sucrose, lactose, fructose, maltose, melase, starches and cellulose, oils and fats such as soybean oil, sunflower oil, peanut oil and coconut oil. fatty acids such as palmitic acid, stearinic acid and linoleic acid, alcohols such as for example glycerin and ethanol and organic acids such as acetic acid. These substances can be used individually or in mixtures. Nitrogen-containing organic compounds such as peptone, yeast extract, meat extract, malt extract, corn steep water, soybean meal and urea or inorganic compounds such as ammonium sulfate, ammonium chloride, phosphate can be used as nitrogen source. of ammonium, ammonium carbonate and ammonium nitrate. The nitrogen sources can be used alone or as mixtures. Phosphoric acid, potassium dihydrophosphate or dipotassium hydrophosphate or the corresponding sodium-containing salts can be used as phosphorus sources. The culture medium must also contain salts of cerium metals, for example magnesium sulfate or iron, which are necessary for growth. Finally, growth promoters such as amino acids and vitamins can be used in addition to the mentioned substances. Suitable pre-stages can be added to the culture medium. The additives mentioned can be added to the culture in the form of a single charge or in a suitable form added during cultivation. To control the pH of the crop, basic compounds such as sodium hydroxide are used, potassium hydroxide, ammonia or acidic compounds such as phosphoric acid or sulfuric acid in suitable form. To control foaming, anti-foaming agents such as fatty acid polyglycol ester or silicone oils can be used. To maintain the stability of the plasmids, selective substances, for example antibiotics, can be added to the medium. To maintain aerobic conditions, oxygen or gaseous mixtures containing oxygen, such as air, are introduced into the culture. The culture temperature is usually at 20 ° C to 45 ° C and preferably at 25 ° C to 40 ° C. The culture is continued until a maximum amount of L-amino acid has been formed. This objective is normally reached in the course of 10 to 160 hours. Methods for the determination of L-amino acids are known in the state of the art. The analysis can be performed as described by Spackman et al. (Analytical Chemistry, 30, 1190 (1958), 1190), by means of anion exchange chromatography with the subsequent derivatization or can be performed by reverse phase CLAP, as described by Lindroth et al. (Analytical Cemistry (1979) 51: 1167-1174). The following microorganisms were deposited in the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany) in accordance with the Budapest Treaty: • Strain DH5oí / pK18mobglyA 'of Escherichia coli as DSM 13170. Examples The present invention will be explained in more detail with the help of the examples of realization. The isolate of the Escherichia coli plasmid DNA as well as all the techniques on restriction treatment with Klenow phosphatase and alkaline were performed according to Sambrook et al. (Molecular Cloning, A laboratory manual (1989) Cold Spring Harbor Laboratory Press). The transformation of Escherichia coli, when not described-something else, was done according to Chung et al. (Proceedings of the National Academy of Sciences of the United States of America USA (1989) 86: 2172-2175). Example 1 Cloning and sequencing of the glyA gene from Corynebacterium glutamicum ATCC13032 The glyA gene was cloned into the cloning vector of E. coli pUC18 (Norrander et al., Gene (1983) 26: 101-106, Roche diagnostics, Mannheim , Germany) . The cloning was done in two steps. First by means of a polymerase chain reaction (PCR) the gene was amplified
Corynebacterium glutamicum ATCC13032 by means of the following oligonucleotide primer derived from the Japanese publication JP-A-0810778d. glyAl-direct: 5 '-GCT TGC AGC GTT TTG CTC TGC C-3' glyAl-inverse: 5 '-ACC CGT AAC CTC TTC CAC ATA GG-3"The PCR reaction was performed in 30 cycles in the presence of 200LTM of deoxynucleotide triphosphates (dATP, dCTP, dGTP, dTTP), each 1 Dm of the corresponding oligonucleotide, 100 ng of chromosomal DNA of Corynebacterium glutamicum ATCC13032, 1/10 volume of reaction buffer lOx, and 2.6 units of a heat stable mixture of Tag / Pwo DNA polymerase (Expand High Fidelity PCTR System from Roche Diagnostics, Mannheim, Germany) in a thermocycle (PTC-100, MJ Research, Inc., Watertown, US) under the following conditions: 94 ° C for 30 seconds, 64 ° C for 1 minutes and 68 ° C for 3 minutes The amplified fragment of approximately 1.7 kb was then ligated with the help of the SureClone Ligation Kit (Amersham Pharmacia Biotech, Uppsala, Sweden) according to the manufacturer's data at the cut point Smal of the pUCld vector. The E. coli strain DH5amcr (Grant et al., Proceedings of the National Academy of Sciences of the United States of America, US (1990) 87: 4645-4649) was transformed. The transformants were identified with the aid of their resistance to carbencillin on LB agar plates containing 50 μg / mL carbencillin. Plasmids were prepared from the 7 transformants and the presence of the 1.7 kb PCR fragment as an insert was verified by restriction analysis. The recombinant plasmid thus formed is referred to below as pUCldglyA. The nucleotide sequence of the 1.7 kb PCR fragment in the pUCldglyA plasmid was determined according to the dideoxy chain interruption method of Sanger et al.
(Proceedings of the National Academy of Sciences of the
United states of .America US (1977) 74: 5463-5467). For this, the entire pUCldglyA insert was sequenced with the help of the next primer. Universal primer: 5 '-GTA AAA CGA CGG CCA-GT-3' Reverse primer: 5 '-GGA AAC AGC TAT GAC CAT G-3' The obtained nucleotide sequences were analyzed with the programming package Lasergene (Biocomputing Software for Windows, DNASTAR, Madison, US). The analysis gave the identification of an open reading marker of 1302 bp in length. The corresponding gene was designated as the glyA gene. The corresponding genetic product covers 434 amino acids and is represented in SEQ. ID. do not. 4. Example 2 Construction of a vector for the reduced expression of glyA The plasmid described in example 1 pUCldglyA was cut with the restriction enzymes EcoRI and Tfil a DNA fragment of 1418 bp in length, which contained the gel glyA without zone own promoter. The 5 'and 3' ends of these fragments were treated with Klenow enzyme. The resulting DNA fragment was thus linearized with BamHI, ligated with the dephosphorylated vector pVWEx2 (Wendisch, "Physiological and NMR spectroscopy investigations on the in vivo activity of the central metabolic pathways in the active strain and in recombinant strains of Corynebacterium glutamicum. ", Jülich Research Center report, Jül-3397, ISSN09442952, Jülich, Germany, 1997), in such a way that the glyA gene is found with the same orientation directly behind the tac promoter inducible with isopropyl-β-D- thiogalactoside (IPTG) of the vector. The E.coli strain DHdoancr (Grant et al., Proceedings of the National Academy of Sciences of the United States of America (1990) 87: 4645-4649) was transformed with the whole binding product. Transformants were identified with the help of their resistance to tetracycline on LB agar plates containing 15 μg / mL tetracycline. Of the 12 transformants plasmids were prepared and by means of restriction analysis the presence of the 1418 bp fragment was verified as an insert in the correct orientation in relation to the tac promoter. The recombinant plasmid thus obtained is referred to below as pVWEx2glyA. From the pVWEx2glyA plasmid then by means of polymerase chain reaction (PCR) by means of the following oligonucleotide primer a DNA fragment was amplified, which contained lacl, the gene for the repressor of the tac promoter, the tac promoter and the first 438 bp of the cloned glyA gene of Corynebacterium glutamicum. glyA-direct (with EcoRI recognition sequence included, marked with underline:) 5 '-CCG GAA TTC CTG CCC GCT TTC CAG TC-3' glyA-inverse (with BamHl recognition sequence included, marked with underline:) 5 ' -CGG GAT CCC AGC TTT CCG GAG AAG TTC AAC-3 'The PCR reaction was performed in 30 cycles in the presence of 200μM of deoxynucleotide triphosphates (dATP, dCTP, dGTP, dTTP), each 1 μm of the corresponding oligonucleotide, 100 ng plasmid DNA of pVWEx21glyA 1/10 volume of reaction buffer lOx, and 2.6 units of a heat stable mixture of DNA polymerase Tag / Pwo
(Expand High Fidelity PCTR System by Roche
Diagnostics, Mannheim, Germany) in a thermocycle (PTC-100,
MJ Research, Inc., Watertown, US) under the following conditions: 94 ° C for 30 seconds, 58 ° C for 30 seconds and 72 ° C for 2 minutes. The amplified fragment of approximately 2.0 kb was then digested with EcoRI and BamHl, with the help of the NucleoSpin Extract 2 in a Macherey-Nagel signature equipment (Duren, Germany) according to the manufacturer's data and then also ligated in the vector cut with EcoRI and BamHl and dephosphorylated pK18mbo (Scháfer et al., Gene (1994) 145: 69-73). The E.coli strain DH5amcr (Grant et al., Proceedings of the National Academy of Sciences of the United States of America, (1990) 87: 4645-4649) was transformed with the whole binding product. Transformants were identified with the aid of their resistance to kanamycin on LB agar plates containing 50 μg / mL kanamycin. Plasmids were prepared from the 12 transformants and by means of restriction analysis the presence of the 2.0 kb fragment was verified as an insert. The recombinant plasmid thus obtained is referred to below as pK18mobglyAr (see Figure 1). Example 3 Construction of the Corynebacterium glutamicum strain ATCC13032:: pK18mobglyA 'with reduced and adjustable glyA expression By means of electroporation (Haynes 1989, FEMS Microbiology Letters 61: 329-334) the empty vector pZl (Menkel et al. , Applied and Environmental Microbiology 81989) 64: 549-554) and the plasmid pK18mobglyA 'described in Example 2 in the native strain Corynebacterium gl utamicum ATCC 13032 (Abe et al., Journal of General and Applied Microbiology (1967) 13: 279-301). After transformation with pZ1 transformants were identified with the aid of their kanamycin resistance on LBHIS agar plates containing 15 μg / mL kanamycin (Liebl et al., FEMS Microbiology Letters (1989) 65: 299-304) . Plasmids were prepared from the 3 transformants and the presence of the empty pZl vector was verified by means of restriction analysis. In this way, the control strain of Corynebacterium glutamicum ATCC13032 / pZ1 was formed. After transformation with pKldmobglyA 'the plasmid had to be integrated by homologous recombination of the 5' cloned end of glyA into the chromosome of Corynebacterium glutamicum ATCC13032.- The kanamycin-resistant clones obtained were identified on LBHIS agar plates containing 15 μg / mL kanamycin and 1 mM isopropyl-β-thiogalactosidase (IPTG) (Liebl et al., FEMS Microbiology Letters (1989) 65: 299-304). The correct integration of pK18mobglyA 'into the chromosome was verified in 2 integration mutants obtained by means of a polymerase chain reaction (PCR) by means of the following oligonucleotide primer. reverse primer (RSP): 5 '-GGA AAC AGC TAT GAC CAT G-3' glyA2-inverse: 5 * -CGG GAT CCC AGC TTT CCG GAG AAG TTC AAC-3 'The PCR reaction was performed in 30 cycles in the presence of 200μM of deoxynucleotide triphosphates (dATP, dCTP, dGTP, dTTP), each 1 μm of the corresponding oligonucleotide, 100 ng of chromosomal DNA of Corynebacterium glutamicum ATCC13032:: pK18mobglyA ', 1/10, 1/10 volume of reaction buffer lOx , and 2.6 units of a heat stable mixture of Tag / Pwo DNA polymerase (Expand High Fidelity PCTR System from Roche Diagnostics, Mannheim, Germany) in a thermocycle (PTC-100, MJ Research, Inc., Watertown, US ) under the following conditions: 94 ° C for 30 seconds, 40 ° C for 30 seconds and 72 ° C for 2 minutes. In this manner, the strain of Corynebacterium glutamicum ATCC13032:: pK18mobglyA 'was formed, in which the glyA gene is under the control of the tac promoter inducible with isopropyl-β-D-thiogalactosidase (IPTG). Example 4 Determination of the serine hydroxymethyltransferase activity encoded by the glyA gene in the strain of Corynebacterium glutamicum ATCC13032:: pK18mobglyA * To obtain the crude extracts for the determination of the serine hydroxymethyltransferase activity encoded by the glyA gene The strains described in example 3 of C. glutamicum ATCC13032 / pZ1 and C. glutamicum ATCC13032:: pK18mobglyA 'in 100 ml of brain heart infusion medium (Difco Laboratories, Detroit, US) with 25 μg / ml kanamycin were precultured. and 100 μM isopropyl-β-D-thiogalactosidase (IPTG) for 14 hours at
° C. The cells were then washed once with 0.9%
(w / v) of sodium chloride solution and with this suspension, 100 ml of CgXII medium were inoculated, so that OD600 (optical density at 600 nm) was 0.5. The medium was identical to the medium described by Keilhauer et al. (Journal of Bacteriology (1993) 175: 5593-5603), additionally containing 25 μg kanamycin / ml and 0, 10 or 100 μM isopropyl-β-D-thiogalactosidase (IPTG). The composition of the medium described by Keilhauer et al. it is represented in table 1. Table 1 Composition of the CGXII medium
The culture of both strains is reacted C. After 10 hours the cells were washed once with 50 mM of 4- (2-hydroxyethyl) -1-piperazinetansulfonic acid / sodium hydroxide buffer (pH 7.0), centrifuged ( 10 minutes at 5000 revolutions per minute with a Minifuge RF from Heraeus, Osterode, Germany) and resuspended in 200 mM of 4- (2-hydroxyethyl) -1-piperazinetansulfonic acid / sodium hydroxide buffer (pH 7.90), in such a way that the final volume was 5 ml. To this cell suspension was added 50 μl of a 2mM solution of pyridoxal 5-phosphate and 50 μl of 100mM dithiothreitol solution and the cells were opened. The cell opening was performed at 0 ° C by means of an ultrasound disintegrator (Branson Sonifier W-250, Branson Sonic Power CO. Danbury, US; duration of sonification 6 minutes, pulse length 100%, intensity of sonification 2.5). After the ultrasound treatment, the cell debris was separated by means of centrifugation (30 minutes at 4 ° C and 13,000 rpm in a refrigerated Sigma 202 MK centrifuge from Sigma-Aldrich, Deisenhofen, Germany). The residue was used as cell-free crude extract directly to determine the enzymatic activity. The determination of the proteins in cell-free crude extracts was performed photometrically according to Bensadoun and Weinstein (Analytical Biochemistry (1976) 70: 241-250). The protein content was determined through a curve formed with bovine serum albumin as standard. To determine the activity of the serine hydroxymethyltransferase in cell-free crude extracts, a discontinuous enzyme test was used, with which the glycine formed from the threonine substrate was quantified. The reaction product was incubated with the following composition (modified according to Scrimgeour and Huennekens, Methods in Enzymology (1962), vol.V: 83d-843, Academic Press) for 15 minutes at 37 ° C; 20mM threonine, 200μM pyridoxal-5-phosphate, 900μM tetrahydrofolate, 100mM 4- (2-hydroxyethyl) -1-piperazinetansulfonic acid / sodium hydroxide buffer (pH 7.0) and 1.0-1.5 mg protein (from extract crude) in a final volume of 1 ml. The reaction was stopped by the addition of 0.25 volume 25% (w / v) trichloroacetic acid solution. The product was incubated for 15 minutes at 0 ° C and the denatured protein was centrifuged (15 minutes at 4 ° C and 13,000 rpm in a refrigerated Sigma 202 MK centrifuge from Sigma-Aldrich, Deisenhofen, Germany). The quantitative determination of the glycine formed in the enzymatic test as a residue was carried out by reverse phase CLAP (Lindroth et al., Analytical Chemistry (1979) 51: 1167-1174). An apparatus for CLAP of the HP1100 series (Hewlett-Packard, Waldbronn, Germany) equipped with fluorescence detector (G1321A) was used; The control of the system and the evaluation of the data was carried out with an HP-Chem-Station (Hewlett-Packard). 1 μl of the amino acid solution to be analyzed was mixed in an automatic previous column derivatization with 20 μL of ortho-fatalaldehyde / 2-mercaptoethanol ready-to-use reagent (Pierce Europe BV, Uid-Beijerland, The Netherlands). The fluorescent thiosubstituted isoindoles thus formed (Jones et al., Journal of Chro atography (1983) 266: 471-482) were separated through a combined precolumn (40x4 mm Hypersil ODS 5) and a main column (Hypersil ODS 5, both columns of the firm CS-Chromatographie Service Gm, bH, Langerwehe, Germany) with a gradient program with a non-polar increasing phase (methanol). The polar eluent was sodium acetate (0.1 molar, pH 7.2); the flow rate was 0.8 ml per minute. The fluorescence detection of the derivatized amino acids was performed at an excitation wavelength of 230 nm and an emission wavelength of 450 nm. Glycine concentrations were calculated through a comparison with an external standard and asparagine as an additional internal standard. The results of the enzymatic test with threonine as a substrate are given in Table 2. Table 2:
Example 5 Construction of strain Brevibacterium flavum DM368-2:: pK18mobglyA 'with reduced and adjustable expression of glyA By means of electroporation (Haynes 1989, FEMS Microbiology Letters 61: 329-334) the empty pZl vector was introduced (Menkel et al. ., Applied and Environmental Microbiology 81989) 64: 549-554) and plasmid pKldmobglyA 'described in Example 2 in the threonine-forming strain Brevibacterium flavum DM368-2. Strain DM368-2 is described in EP-B-0 385 940 and is deposited as DSM5399. After transformation with pZ1 transformants were identified with the aid of their kanamycin resistance on LBHIS agar plates containing 15 μg / mL kanamycin (Liebl et al., FEMS Microbiology Letters (1989) 65: 299-304) . Plasmids were prepared from the 3 transformants and the presence of the empty pZl vector was verified by means of restriction analysis. In this way, the control strain was formed
Brevibacterium flavum DM368-2 / pZl. After transformation with pK18mobglyA 'the plasmid had to be integrated by homologous recombination of the 5' cloned end of glyA into the chromosome of Brevibacterium flavum DM368-2 / pZl. The obtained kanamycin-resistant clones were identified on LBHIS agar plates containing 15 μg / mL kanamycin and 1 mM isopropyl-β-thiogalactosidase (IPTG) (Liebl et al., FEMS Microbiology Letters (19d9) 65: 299-304 ). The correct integration of pKldmobglyA 'in the chromosome was verified in 4 integration mutants obtained by means of a polymerase chain reaction (PCR) as already described in example 3, with 100 ng of chromosomal DNA of Brevibacterium flavum DM368- 26 2:: pK18mobglyA 'as a template. In this manner, the strain Brevibacterium flavum DM366-2 was formed:: pK18mobglyA *, in which the glyA gene under the control of the tac promoter is inducible with isopropyl-β-thiogalactosidase Example 6 Determination of the serine hydroxymethyltransferase activity encoded by glyA in strain Brevibacterium flavum DM368-2:: pK18mobflyA 'Obtaining crude extracts for the determination of serine hydroxymethyltransferase activity encoded by glyA in the strains of B. flavum DM36d-2 / pZl and B. flavum DM368-2: : pKldmobglyA 'described in example 5, was carried out as described already in example 4. The determination of the proteins in the cell-free crude extracts obtained and the discontinuous enzymatic test, in which the glycine formed from the substrate of threonine were also performed as described in example 4. The results of these enzymatic tests with threonine as a substrate are shown in table 3. Table 3:
2. 3
Example 7: Preparation of L-threonine with Brevibacterium flavum To study its threonine formation, the strains of B. flavum DM368-2 / pZ1 and DM369-2 were pre-cultured: pKldmobglyA * described in example 5 in 100 ml of infusion medium Brain heart (Difco Laboratories, Detroit, US) with 25 μg / mL kanamycin and 100 μM isopropyl-β-D-thiogalactosidase (IPTG) for 14 hours at 30 ° C. The cells were then washed once with 0.9% (w / v) of sodium chloride solution and with this suspension, 100 ml of CgXII medium were inoculated, so that OD600 (optical density at 600 nm) was 0.5 The medium was identical to the medium described by Keilhauer et al. (Journal of Bacteriology (1993) 175: 5593-5603), additionally containing 25 μg kanamycin / ml and 0, 10 or 100 μM isopropyl-β-D-thiogalactosidase (IPTG). Culture of both strains was carried out at 30 ° C for a period of 72 hours. After 4d and 72 hours samples were taken and the cells were centrifuged briefly (5 minutes at 13000 rpm with a Biofuge peak from the firm Heraeus, Osterode, Germany). The quantitative determination of the extracellular amino acid concentrations of the culture residue was carried out as already described in example 4 by means of reverse phase CLAP (Lindroth et al., Analytical Chemistry (1979) 51: 1167-1174). Threonine concentrations were calculated through a comparison with an external standard and asparagine as an additional internal standard. The results are given in table 4. Table 4:
The following figures are included: Figure 1: map of plasmid pKldmobglyA '. The data on the length should be understood as approximate values. The abbreviations and denominations used have the following meanings: • BamHl: restriction endonuclease of Bacillus amyl ol i guefa ci ens • BglII: restriction endonuclease of Bacillus globigii • BstEII: restriction endonuclease of Bacillus stearothermophilus • EcoRI: restriction endonuclease of Escherichia coli
• EcoRV: restriction endonuclease of Escherichia coli m HindIII: restriction endonuclease of Haemophilus influezae • Sacl: restriction endonuclease of Streptomyces achromogenes • kan: kanamycin resistance gene • laclq: tac promoter repressor gene Ptac • Ptac: tac • glyA 'promoter: section 5' of the serine hydroxymethyltransferase gene • glyA2-inverse: primer to verify an integration
• RSP: reverse standard primer to verify an integration. It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention.
Claims (6)
- CLAIMS Having described the invention as above, it is claimed as property contained in the following claims: 1.- Procedure for the preparation of L-amino acids characterized because the following steps are carried out: a) fermentation of coryne-producing bacteria of L- amino acids, in which at least the glyA gene is weakened, b) enrichment of the desired product in the medium or in the cells of the bacteria, and c) isolated from the L-amino acids.
- 2. Method according to claim 1, characterized in that bacteria are used in which additional genes of the biosynthetic pathway of the desired L-amino acids are additionally reinforced.
- 3. Method according to claim 1, characterized in that bacteria are used in which the metabolic pathways that reduce the formation of the desired L-amino acids are at least partially deactivated.
- 4. Method according to claim 1, characterized in that the expression of the polynucleotide encoding the glyA gene is reduced.
- 5. Process according to claim 1, characterized in that the catalytic properties of the polypeptide (enzyme protein), which codes for the glyA polynucleotide, are reduced.
- 6. Method according to claim 1, characterized in that to achieve the weakening the process of integrating mutagenesis of the vector pKldmobglyA ', represented in Figure 1 and deposited in E.coli as DSM 13170, is used. - Process according to claim 1, characterized in that for the preparation of L-threonine bacteria are fermented in which simultaneously they are overexpressed, especially one or more genes, selected from the group formed by: i) the hom gene encoding homoserin dihydrogenase ii) the gap gene encoding the glyceraldehyde 3-phosphate dihydrogenase iii) the pyc gene coding for pyruvate carboxylase iv) the mqo gene coding for malate oxidoreductase: quinone V ) the thrE gene coding for the export of threonine. d.- Method according to claim 1, characterized in that bacteria are fermented for the production of L-threonine, in which simultaneously one or several of the genes, selected from the group of i) the pck gene coding for the carbokinase, are simultaneously weakened of phosphoenolpyruvate ii) the poxB gene coding for pyruvate oxidase. 9. Method according to one or more of the preceding claims, characterized in that microorganisms of the genus Corynebacterium gl utamicum are used. 10.- Coryneform bacteria, characterized in that the glyA gene weakens in them. 11.- Vector pKldmobglyA ', represented in figure 1 and deposited in E. coli as DSM 13170. 12.- Isolated polynucleotide, characterized in that they contain: (i) the nucleotide sequence of the lad-tac-5'glyA unit, shown in SEQ.ID.no. 2, or (ii) at least one sequence corresponding to the sequences (i) within the degeneracy range of the genetic code, or (iii) at least one sequence that hybridizes with the sequences complementary to the sequences (i) or ( ii), and eventually (iv) neutral function sense mutations in (i). 13. Isolated polynucleotide, characterized in that it contains (i) the nucleotide sequence of the lacI-tac-glyA unit, shown in SEQ. ID. do not. 3, or (ii) at least one sequence corresponding to the sequences (i) within the degeneracy range of the genetic code, or (iii) at least one sequence that hybridizes with the sequences complementary to the sequences (i) or ( ii), and eventually (iv) neutral function sense mutations in (i).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19959329.9 | 1999-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00012041A true MXPA00012041A (en) | 2002-06-05 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6913909B2 (en) | Nucleotide sequences coding for the thrE gene and process for the enzymatic production of L-threonine using coryneform bacteria | |
EP1297148B1 (en) | Nucleotide sequences which code for the mdha gene from corynebacterium glutamicum | |
SK10202000A3 (en) | L-lysine producing coryneform bacteria and method for the production of l-lysine | |
JP2001169788A (en) | Nucleotide sequence encoding extrusion of branched amino acid, method for isolating the same and use thereof | |
US20030199045A1 (en) | Process for the preparation of L-amino acids with amplification of the zwf gene | |
SK1942000A3 (en) | PROCESS FOR THE FERMENTATIVE PRODUCTION OF L-AMINO ACIDS USINGì (54) CORYNEFORM BACTERIA | |
SK287997B6 (en) | Isolated gene of Corynebacterium glutamicum, recombinant coryneform bacteria and process for preparation of L-lysine or L-threonine | |
US6596516B2 (en) | Process for the fermentative preparation of L-amino acids using coryneform bacteria | |
EP1367130B1 (en) | Process for the preparation of L-lysine using coryneform bacteria which contain an attenuated malate enzyme gene | |
US20050112733A1 (en) | Process for the preparation of L-amino acids with amplification of the zwf gene | |
SK16542001A3 (en) | Process for the fermentative preparation of l-amino acids with amplification of the gnd gene | |
CA2301407A1 (en) | Production of l-amino acids by fermentation using coryneform bacteria | |
US20020028490A1 (en) | Process for the production of L-amino acids by fermentation using coryneform bacteria | |
SK7442000A3 (en) | Method for the fermentative preparation of l-amino acids and nucleotide sequences coding for the accda gene | |
CA2309481A1 (en) | A process for the fermentative preparation of l-amino acids using coryneform bacteria | |
SK16692000A3 (en) | Process for the fermentative preparation of l-lysine by using coryneform bacteria | |
US8334126B2 (en) | Coryneform host-vector systems comprising a chromosomal ALR gene which is attenuated or eliminated and methods of using | |
MXPA00012041A (en) | Process for the fermentative production of l-amino acids employing coryneform bacteria in which the glya gene activity has been decreased | |
US20030092139A1 (en) | Process for the fermentative preparation of L-amino acids using coryneform bacteria | |
US20020106754A1 (en) | Nucleotide sequences which codes for the alr gene | |
MXPA01003367A (en) | New ribosomal l1 protein gene from coryneform bacteria, useful, when downregulated, for increasing fermentative production of amino acids. | |
MXPA00001638A (en) | Process for the fermentative production of l-amino acids using coryneform bacteria |